Safety of systemic therapy for noninfectious uveitis-Reference-Cited by-同舟云学术

Safety of systemic therapy for noninfectious uveitis

Published:2019-12-02 Issue:12 Volume:18 Page:1219-1235
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Ormaechea Maria Soledad¹²,Hassan Muhammad²,Onghanseng Neil²,Park Jung Hyun²³,Mahajan Sarakshi²,Al-Kirwi Khalid Yusuf²⁴,Uludag Gunay²,Halim Muhammad Sohail²,Schlaen Ariel¹,Sepah Yasir J²,Do Diana V²,Nguyen Quan Dong²

Affiliation:

1. Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina

2. Byers Eye Institute, Stanford University, Palo Alto, CA, USA

3. Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

4. Department of Ophthalmology, Imamein Khadhimein Medical City University Hospital, Baghdad, Iraq

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2019.1692810

Reference261 articles.

1. Uveitis: A Potentially Blinding Disease

2. The Standardization of Uveitis Nomenclature (SUN) Project

3. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcomes of noninfectious uveitis treated with systemic immunomodulatory therapy: a retrospective case series;Canadian Journal of Ophthalmology;2024-06

2. Subconjunctival injection of rapamycin-loaded polymeric microparticles for effective suppression of noninfectious uveitis in rats;International Journal of Pharmaceutics;2024-05

3. AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?;Expert Reviews in Molecular Medicine;2024

4. Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis;Journal of Biosciences and Medicines;2024

5. Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases;Advanced Drug Delivery Reviews;2023-07